Overview
- CagriSema combines semaglutide 2.4 mg with the amylin analogue cagrilintide 2.4 mg and, if approved, would be the first injectable pairing of these mechanisms.
- The application cites phase 3 REDEFINE data showing 20.4% average weight loss at 68 weeks versus 3.0% with placebo, with 22.7% on an on‑treatment analysis.
- Additional trial readouts reported that 91.9% of participants on CagriSema lost at least 5% of body weight and 54% reached a non‑obesity threshold by week 68.
- Eli Lilly said it has filed for FDA approval of orforglipron, a daily oral GLP‑1 that maintained prior weight loss after Wegovy or Zepbound, and reported 28.7% loss at 68 weeks with its triple‑agonist retatrutide.
- Pfizer moved to enter the category with a YaoPharma deal for an oral GLP‑1 (YP05002) and plans to acquire Metsera, as a Harvard analysis reported little or no effect of GLP‑1s on risks of several obesity‑related cancers.